March 2022 COVID-19 Updates
Background:
Two manufacturers of Covid-19 vaccines have submitted additional requests for Emergency Use Authorization (EUA) for children ages 6 months to 4 years and boosters for those fully vaccinated adults. There is a new Covid-19 test to identify mutations as well. We feel it is important to keep you abreast of the latest Covid-19 news in this ever-changing environment. This release highlights the new codes released by the American Medical Association (AMA) and provides details of the new diagnosis codes for Covid-19 vaccine status, taking effect on April 1, 2022.
Please note the following:
-
- The Food and Drug Administration (FDA) has postponed the review of the Pfizer Vaccination for children ages 6 months to 4 years until all the clinical trial data is available for review.
- Pfizer summited a request for EUA for a booster for adults 65 or older who are at risk of severe illness from Covid-19, the FDA is currently reviewing the request.
- The FDA authorized shortening of the time period for Pfizer boosters to five months.
- Moderna received approval from the FDA to market its Covid-19 vaccine under the trade name of Spikevax in January of 2022.
- Moderna also submitted a EUA request for a second booster for those over the age of 18 which the FDA is currently reviewing.
- The AMA has published additional vaccine and administration codes pending the EUA for the boosters and new vaccines.
- The AMA released a new CPT code (87913) to test for mutations of Covid-19 on 2-21-2022.
- The Center for Disease Control (CDC) has released new diagnosis codes to reflect Covid-19 vaccination status.
- Breaking news: Moderna will be submitting a request for EUA for vaccination for children ages 6 months to 6 years of age next week based on the results of their clinical trial per media reports.
Below are the Vaccination Status Diagnosis Codes Released by the CDC
Diagnosis Code | Description | Effective Date |
Z28.311 | Partial Vaccination for Covid-19 | 4/1/22 |
Z28.310 | Unvaccinated for Covid-19 | 4/1/22 |
Z28.39 | Other Under Immunization Status | 4/1/22 |
New Test for Covid-19 Mutations
CPT Code | Description | Effective Date |
87913 | NFCT AGENT GENOTYPE ALYS NUCLEIC ACID SARSCOV2 | 2/21/22 |
New Vaccine and Administration Codes
Code | Description | EUA Date | Manufacturer | Age Group | Dosage |
91307 | Vaccine-reconstituted | 10/29/21 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
0071A | Admin 1st Dose | 10/29/21 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
0072A | Admin 2nd Dose | 10/29/21 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
0073A | Admin 3rd Dose | 1/3/22 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
Code | Description | EUA Date | Manufacturer | Age Group | Dosage |
91308 | Vaccine-reconstituted | Pending | Pfizer | 6 Mo – 4 Years | 3 mcg/0.2 mL |
0081A | Admin 1st Dose | Pending | Pfizer | 6 Mo – 4 Years | 3 mcg/0.2 mL |
0082A | Admin 2nd Dose | Pending | Pfizer | 6 Mo – 4 Years | 3 mcg/0.2 mL |
Code | Description | EUA Date | Manufacturer | Age Group | Dosage |
91309 | Vaccine | Pending | Moderna | Over 18 | 50 mcg/0.5 mL |
0094A | Admin booster | Pending | Moderna | Over 18 | 50 mcg/0.5 mL |
Reference Materials:
- MLN Link MM12578. January 14, 2022
https://www.cms.gov/files/document/mm12578-april-2022-update-medicare-severity-diagnosis-related-group-ms-drg-grouper-and-medicare-code.pdf
- AMA Discussion on Vaccine Status for Kids
https://www.ama-assn.org/delivering-care/public-health/tsa-mask-mandate-updates-covid-vaccines-kids-andrea-garcia-jd-mph
- FDA Press Release January 3, 2022
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine
- HealthLeaders Media Article on Moderna Seeking EUA
https://www.npr.org/2022/03/23/1088167753/moderna-covid-19-vaccine-children-fda
If you are interested in learning more about Codoxo’s forensic AI platform or would like to speak to Codoxo team member, contact us via info@codoxo.com.
FORENSIC AI PLATFORM
Our Forensic AI Engine analyzes your data, detects problems, and builds connections across your data to provide actionable insights
Insight Scope
For everyone across the health plan
Clinical Scope
For clinical teams
Audit Scope
For everyone across the health plan and PBM
Network Scope
For network teams
Payment Scope
For payment integrity teams
Provider Scope
For network and payment teams
Fraud Scope
For SIU teams
SERVICES
We provide a full range of professional services, from data migration and ongoing customer success through flexible virtual SIU options.